1. Record Nr. UNINA9910437996003321

Titolo	Antibody-drug conjugates and immunotoxins : from pre-clinical development to therapeutic applications / / Gail Lewis Phillips, editor
Pubbl/distr/stampa	New York, : Humana Press, 2013
ISBN	1-283-93413-2 1-4614-5456-5
Edizione	[1st ed. 2013.]
Descrizione fisica	1 online resource (369 p.)
Collana	Cancer drug discovery and development
Altri autori (Persone)	PhillipsGail Lewis
Disciplina	615.37 615.373
Soggetti	Antibody-drug conjugates Antibody-toxin conjugates
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	pt. I. Introduction and development perspectives -- pt. II. Development of antibody-drug conjugates -- pt. III. Selection of cytotoxic agents -- pt. IV. Antibody-drug conjugates for hematologic malignancies -- pt. V. Antibody-drug conjugates for solid tumors -- pt. VI. Metabolism -- pt. VII. Immunotoxins.
Sommario/riassunto	The concept of delivering ‘magic bullets’ to treat diseases was first proposed by Paul Erlich in the early 1900’s. The realization of this concept for the treatment of cancer occurred in the late 1990’s with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the

volume highlights the promise that this technology holds for diverse types of human cancer.